Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6793 in healthy Japanese and Chinese participants
NCT06368440Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD6793 (5 cohorts), sponsored by AstraZeneca. Primary endpoint: Adverse Events. Started May 2024; status: completed.
02
Drugs
AZD6793
Beyond the preview
Go deeper on NCT06368440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368440.